Lecanemab (BAN2401) Phase 2b study in early Alzheimer's disease published in peer-reviewed journal, Alzheimer's Research & Therapy |
| April 20, 2021 | April 2021 Bond Updates |
|
STOCKHOLM, April 20, 2021 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced the publication of an article, A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimer's Disease with Lecanemab, an Anti-Aβ Protofibril... |
| View more at: https://www.prnewswire.com:443/news-releases/lecanemab-ban2401-phase-2b-study-in-early-alzheimers-disease-published-in-peer-reviewed-journal-alzheimers-research--therapy-301272183.html |
| Related News |
|